CMC Pharma Consulting BJ ApS: Financial statements 2023
CVR: 41988592
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
CMC Pharma Consulting BJ ApS (CVR 41988592) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 4,949,668 and a net result of DKK 111,571 compared with DKK 345,175 the year before. That is a decrease of 4.4% compared with the year before. Equity in the 2023 report amounted to DKK 207,967. The solvency ratio was 33.9%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 4,949,668
- Profit/Loss
- DKK 111,571
- Equity
- DKK 207,967
- Total Assets
- DKK 614,130
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 4.9M | 112K | 208K | 1 |
| 2022 | - | 5.2M | 345K | 396K | 1 |
| 2021 | - | 3.5M | 611K | 651K | 1 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
CMC Pharma Consulting BJ ApS has published its annual report for 2022. Gross profit came to DKK 5,176,271, and the net result was DKK 345,175.
About CMC Pharma Consulting BJ ApS
CMC Pharma Consulting BJ ApS is a Danish company of the type Anpartsselskab based in Rungsted Kyst, founded in 2021. The company is registered under the industry Anden teknisk rådgivning. The management consists of Babak Jamali. The company is owned by Babak Jamali. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 1,764,114 and a net result of DKK 30,653 compared with DKK 127,570 the year before. Equity in the 2025 report amounted to DKK 111,190.